{
    "article_link": "https://www.frontiersin.org/articles/10.3389/fcell.2021.649265/full",
    "data": [
        {
            "id": "data_1",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163574",
            "format": "CEL (raw), TXT (processed)",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE163574"
        },
        {
            "id": "data_2",
            "omics": "Proteomics",
            "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023344",
            "format": "RAW/mzXML",
            "source": "ProteomeXchange",
            "public_id": "PXD023344"
        },
        {
            "id": "data_3",
            "omics": "Phosphoproteomics",
            "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023345",
            "format": "RAW/mzXML",
            "source": "ProteomeXchange",
            "public_id": "PXD023345"
        },
        {
            "id": "data_4",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62452",
            "format": "TXT",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE62452"
        },
        {
            "id": "data_5",
            "omics": "Transcriptomics",
            "link": "https://portal.gdc.cancer.gov/",
            "format": "RNA-seq",
            "source": "The Cancer Genome Atlas (TCGA)",
            "public_id": "TCGA-PAAD"
        },
        {
            "id": "data_6",
            "omics": "Transcriptomics",
            "link": "https://dcc.icgc.org/",
            "format": "RNA-seq",
            "source": "International Cancer Genome Consortium (ICGC)",
            "public_id": "ICGC_AU"
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Cytotoxicity Assessment",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_2",
            "analysis_name": "Differential analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_3",
            "analysis_name": "Ingenuity Pathway Analysis (IPA)",
            "analysis_data": [
                "data_1"
            ],
            "label": null
        },
        {
            "id": "analysis_4",
            "analysis_name": "TMT-based quantitative proteomics",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_5",
            "analysis_name": "TMT-based phosphoproteomics",
            "analysis_data": [
                "data_3"
            ],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "Integrated analysis",
            "analysis_data": [
                "analysis_2",
                "analysis_4",
                "analysis_5"
            ],
            "label": null
        },
        {
            "id": "analysis_7",
            "analysis_name": "Prognostic Signature Construction",
            "analysis_data": [
                "analysis_6",
                "data_4",
                "data_5",
                "data_6"
            ],
            "label": {
                "Risk score": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_8",
            "analysis_name": "Univariate Cox Regression",
            "analysis_data": [
                "analysis_7",
                "data_4",
                "data_5",
                "data_6"
            ],
            "label": {
                "Risk score": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "LASSO Cox Regression",
            "analysis_data": [
                "analysis_6",
                "data_4",
                "data_5",
                "data_6"
            ],
            "label": {
                "Risk score": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_10",
            "analysis_name": "Multivariate Cox Regression",
            "analysis_data": [
                "analysis_9"
            ],
            "label": {
                "Risk score": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_11",
            "analysis_name": "Gene Set Enrichment Analysis (GSEA)",
            "analysis_data": [
                "analysis_7",
                "data_4",
                "data_5",
                "data_6"
            ],
            "label": {
                "Risk score": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_12",
            "analysis_name": "GO analysis",
            "analysis_data": [
                "analysis_4"
            ],
            "label": null
        },
        {
            "id": "analysis_13",
            "analysis_name": "KEGG analysis of differentially expressed proteins",
            "analysis_data": [
                "analysis_4"
            ],
            "label": null
        },
        {
            "id": "analysis_14",
            "analysis_name": "KEGG analysis of differentially phosphorylated proteins",
            "analysis_data": [
                "analysis_5"
            ],
            "label": null
        },
        {
            "id": "analysis_15",
            "analysis_name": "Domain enrichment analysis",
            "analysis_data": [
                "analysis_5"
            ],
            "label": null
        },
        {
            "id": "analysis_16",
            "analysis_name": "Cell Cycle Distribution Analysis",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_17",
            "analysis_name": "Apoptosis Rate Analysis",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_18",
            "analysis_name": "Invasion Capability Analysis",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_19",
            "analysis_name": "Wound Healing Rate Analysis",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_20",
            "analysis_name": "Western Blot Analysis",
            "analysis_data": [],
            "label": {
                "Treatment": [
                    "anlotinib",
                    "DMSO"
                ]
            }
        },
        {
            "id": "analysis_21",
            "analysis_name": "qRT-PCR Validation",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "Validation Type": [
                    "Up-regulated",
                    "Down-regulated"
                ]
            }
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_1",
            "metrics": "IC50",
            "value": "5.535 μM (PANC-1) and 4.642 μM (AsPC-1)",
            "features": null
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Number of DEGs",
            "value": "992",
            "features": null
        },
        {
            "analysis_id": "analysis_3",
            "metrics": "Enriched pathways",
            "value": "24 cancer-related canonical pathways",
            "features": [
                "Unfolded protein response (most significant)",
                "Cell cycle: G2/M DNA damage checkpoint regulation",
                "Role of BRCA1 in DNA damage response",
                "p53 signaling pathway"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Up-regulated and Down-regulated Proteins",
            "value": "725 up-regulated, 321 down-regulated",
            "features": [
                "LAPM1",
                "LAMP2",
                "CDC25C",
                "CKS1B",
                "PRKDC",
                "PLK1",
                "CDK1",
                "TOP2A"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Number of differentially phosphorylated proteins",
            "value": "1,753",
            "features": [
                "CDC25C (down-phosphorylated)",
                "CDK1 (up-phosphorylated)",
                "mTOR signaling",
                "DNA damage checkpoint regulators"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "Shared mechanisms",
            "value": "Post-transcriptional regulation of ribosome and lysosome",
            "features": [
                "Ribosome biogenesis",
                "Lysosomal function",
                "ATM",
                "GADD45A",
                "p53 signaling pathway"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "Proportion in high-risk group",
            "value": "57%",
            "features": [
                "TOP2A",
                "CRABP2",
                "CDK1",
                "NUSAP1",
                "PERP"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": "AUC",
            "value": "0.7 (3 years), 0.72 (5 years) - TCGA; 0.87 (3 years), 0.85 (5 years) - GSE62452; 0.65 (3 years), 0.75 (5 years) - ICGC_AU",
            "features": null
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "Selected genes",
            "value": "5 genes: TOP2A, CRABP2, CDK1, NUSAP1, and PERP",
            "features": [
                "TOP2A",
                "CRABP2",
                "CDK1",
                "NUSAP1",
                "PERP"
            ]
        },
        {
            "analysis_id": "analysis_10",
            "metrics": "Hazard Ratio (HR)",
            "value": "2.318 (risk score, 95% CI = 1.4569–3.688, p = 0.000388); 1.831 (N stage, 95% CI = 1.0647–3.148, p = 0.028755)",
            "features": [
                "risk score",
                "N stage"
            ]
        },
        {
            "analysis_id": "analysis_11",
            "metrics": "Enriched pathways",
            "value": "33 pathways significantly enriched in high-risk subgroup",
            "features": [
                "Nucleotide excision repair",
                "Mismatch repair",
                "Homologous recombination",
                "Base excision repair",
                "Cell cycle",
                "p53 signaling pathway",
                "DNA replication",
                "Spliceosome",
                "RNA degradation",
                "Aminoacyl tRNA biosynthesis",
                "Pancreatic cancer",
                "Small cell lung cancer"
            ]
        },
        {
            "analysis_id": "analysis_12",
            "metrics": "Enriched GO terms",
            "value": "Components of ribosome and rRNA binding",
            "features": [
                "Structural constituent of ribosome",
                "rRNA binding"
            ]
        },
        {
            "analysis_id": "analysis_13",
            "metrics": "Enriched KEGG pathways",
            "value": "ribosome, lysosome",
            "features": [
                "Ribosome",
                "Lysosome"
            ]
        },
        {
            "analysis_id": "analysis_14",
            "metrics": "Enriched KEGG pathways",
            "value": "RNA transport, spliceosome, cell cycle, regulation of actin cytoskeleton",
            "features": [
                "Spliceosome",
                "RNA degradation",
                "Regulation of actin cytoskeleton",
                "mTOR signaling"
            ]
        },
        {
            "analysis_id": "analysis_15",
            "metrics": "Enriched domains",
            "value": "RNA-binding domain superfamily, RNA recognition motif domain, nucleotide-binding alpha-beta plait domain superfamily",
            "features": [
                "RNA-binding domain superfamily",
                "RNA recognition motif domain",
                "nucleotide-binding alpha-beta plait domain superfamily"
            ]
        },
        {
            "analysis_id": "analysis_16",
            "metrics": "Cell cycle phase distribution",
            "value": "Ratio of G2/M phase cells increased, G1 phase decreased (p < 0.0001)",
            "features": [
                "PANC-1 cells",
                "AsPC-1 cells"
            ]
        },
        {
            "analysis_id": "analysis_17",
            "metrics": "Apoptosis rate",
            "value": "More than threefold increase in anlotinib-treated cells (p < 0.0001)",
            "features": [
                "PANC-1 cells",
                "AsPC-1 cells"
            ]
        },
        {
            "analysis_id": "analysis_18",
            "metrics": "Invasion capability",
            "value": "Approximately 20% of control in anlotinib-treated cells (p < 0.001)",
            "features": [
                "PANC-1 cells",
                "AsPC-1 cells"
            ]
        },
        {
            "analysis_id": "analysis_19",
            "metrics": "Wound healing rate",
            "value": "Significantly reduced in anlotinib-treated cells (p < 0.001)",
            "features": [
                "PANC-1 cells",
                "AsPC-1 cells"
            ]
        },
        {
            "analysis_id": "analysis_20",
            "metrics": "γH2AX expression",
            "value": "Significantly up-regulated in anlotinib-treated pancreatic cancer cells",
            "features": [
                "γH2AX (marker of DNA double-strand breaks)"
            ]
        },
        {
            "analysis_id": "analysis_21",
            "metrics": "Validation of DEGs",
            "value": "Consistent with transcriptome profiling for 15 up-regulated and 15 down-regulated genes",
            "features": [
                "Validation of gene expression patterns"
            ]
        }
    ]
}